Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer’s Diseases
Authors:
- 29 October 2019
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 16 (9) , 836-842
Abstract
Background: Xanthohumol has been reported to have cytoprotection through activation of Nrf2−ARE signaling pathway and; it has capability of scavenging free radicals, suggesting its potential for the prevention of neurodegeneration. However, the bio-incompatibility and blood-brain barrier impermeability of xanthohumol hindered its in vivo efficacy potential for treating Alzheimer’s disease (AD). Objective: We designed and prepared a series of xanthohumol derivatives to enhance the desirable physical, biological and pharmacological properties in particular the blood-brain barrier permeability for intervention of AD. Methods: We designed and synthesized a novel series of 9 xanthohumol derivatives. Their inhibitory effect on amyloid-β (1-42), Aβ1-42, oligomerization and fibrillation as well as neuroprotection against amyloid-β induced toxicities, were explored. Results: Among the 9 xanthohumol derivatives, some of them exhibited a moderate to high inhibitory effect on Aβ1-42 oligomerization and fibrillation. They were biocompatible and neuroprotective to the SH-SY5Y cells by reducing the ROS generation and calcium uploading that were induced by the amyloid- β. Importantly, two of the derivatives were found to be blood-brain barrier permeable showing promising potential for AD treatment. Conclusion: Two derivatives have been identified to be biocompatible, non-toxic, neuroprotective against Aβ-induced toxicities and blood-brain barrier permeable highlighting their promising potential as AD drug candidates for future clinical use.Keywords
Funding Information
- Collaborative Research Fund of the Hong Kong Research Grant Council (C2012-15G)
- National Natural Sciences Foundation of China (21675135)
This publication has 19 references indexed in Scilit:
- Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase InhibitorsAmerican Journal of Alzheimer's Disease and Other Dementias®, 2016
- 2015 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2015
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothesNature Neuroscience, 2012
- Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers DiseaseCurrent Medicinal Chemistry, 2008
- Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomersNeurobiology of Aging, 2008
- Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's DiseaseThe Journal of Neuroscience, 2007
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivoNature, 2002
- Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic MiceScience, 1996